We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Breathing Adapted Radiotherapy for Mediastinal Lymphoma

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00928096
First Posted: June 25, 2009
Last Update Posted: October 21, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
University of Copenhagen
Information provided by (Responsible Party):
Peter Meidahl Petersen, Rigshospitalet, Denmark
  Purpose
In this study, radiation therapy plans will be made for 20 consecutive patients with mediastinal Hodgkin lymphoma or aggressive non-Hodgkin lymphoma. One plan is done using a breathing adapted pre-chemo PET-CT scan fused with a post-chemo planning CT scan and another plan is done using the standard procedure with pre-chemo PET-CT fused with post-chemo planning CT scan. Dose levels to the lymphoma and to the organs of risk will be compared in each patient. The best radiation therapy plan will be used to treat the patient.

Condition
Lymphoma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Breathing Adapted Radiotherapy for Mediastinal Lymphoma

Resource links provided by NLM:


Further study details as provided by Peter Meidahl Petersen, Rigshospitalet, Denmark:

Primary Outcome Measures:
  • Estimated radiation dose levels to the lymphoma and to the organs of risk [ Time Frame: Before day 1 of radiation therapy ]

Enrollment: 22
Study Start Date: June 2009
Study Completion Date: May 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Detailed Description:

Radiotherapy using a breathing adapted therapy scan is a routine technique in breast cancer. Breathing adapted radiotherapy may also reduce radiation dose to organs at risk, e.g. heart and lung, in patients with mediastinal Hodgkin lymphoma and aggressive non-Hodgkin lymphomas.

Optimal radiation therapy of these lymphoma patients includes radiotherapy planning using pre-chemotherapy PET-scanning, fused with a post-chemo planning CT-scan. This makes accurate treatment of pre-chemo involved volume possible and also accurate radiation of the post-chemo involved volume possible. Thus, the optimal breathing adapted radiation requires planning using a breathing adapted pre-chemo PET-CT scan fused with a breathing adapted post-chemo planning CT scan. In this study, 20 consecutive patients with mediastinal Hodgkin lymphoma and aggressive non-Hodgkin lymphomas will have combination therapy with chemotherapy and radiation therapy to involved nodes. Two radiation therapy plans will be made for each patient: one using a breathing adapted pre-chemo PET-CT scan fused with a post-chemo planning CT scan, and one using the standard procedure of a pre-chemo PET-CT scan fused with post-chemo planning CT scan. Dose levels to the lymphoma and to the organs of risk will be compared in each patient. The best radiation therapy plan will be used to treat the patient.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
20 consecutive patients with mediastinal Hodgkin lymphoma and aggressive non-Hodgkin lymphomas refered to Hematological Clinic, Copenhagen University Hospital, Rigshospitalet
Criteria

Inclusion Criteria:

  • Stage I/II mediastinal Hodgkin lymphoma or aggressive non-Hodgkin lymphomas
  • Treatment plan includes radiotherapy

Exclusion Criteria:

  • Not able to comply to breathing adapted therapy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00928096


Locations
Denmark
Department of Hematology and Department of Radiation Oncology, Copenhagen University Hospital, Rigshospitalet
Copenhagen, Denmark, DK2100
Sponsors and Collaborators
Peter Meidahl Petersen
University of Copenhagen
Investigators
Principal Investigator: Peter M Petersen, MD, Ph.D Rigshospitalet, Denmark
  More Information

Publications:
Responsible Party: Peter Meidahl Petersen, MD.Ph.D, Rigshospitalet, Denmark, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier: NCT00928096     History of Changes
Other Study ID Numbers: HN-gating-001
H-D-2007-0069
First Submitted: June 23, 2009
First Posted: June 25, 2009
Last Update Posted: October 21, 2014
Last Verified: October 2014

Keywords provided by Peter Meidahl Petersen, Rigshospitalet, Denmark:
Lymphoma
Radiotherapy
Positron-Emission Tomography
CT scan

Additional relevant MeSH terms:
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases